real-time news and commentary for investors
Thursday, Sep 12
Sangamo BioSciences announces evidence of HIV functional control with SB-728-T
- Sangamo BioSciences (SGMO) presents what it says is "the first evidence that sustained functional control of HIV in the absence of antiretroviral therapy is possible."
- The company says viral load became undetectable during an ART treatment interruption in three of seven patients treated with SB-728-T.
- In one patient, viral load has been undetectable for seven weeks.
- The company calls this "a major step toward immunological functional control of HIV." (PR)
- SGMO +3.2% AH